coronavirus vaccine so that it can be licenced for general use. The Phase two and three trials of the vaccine study are now being conducted across multiple locations in the UK.
On Monday, researchers found that the vaccine is safe and induces an immune reaction, in the first phases of the study as the findings were published in medical journal, The Lancet.It says: "Our preliminary findings show that the candidate ChAdOx1 nCoV-19 vaccine given as a single dose was safe and tolerated."No serious adverse reactions to ChAdOx1 nCoV-19 occurred.
The majority of adverse events reported were mild or moderate in severity, and all were self-limiting.The study showed that a single dose of ChAdOx1 nCoV-19 elicits an increase in spike-specific.